¼¼°èÀÇ ÁøÆóÁõ ½ÃÀå º¸°í¼­(2025³â)
Pneumoconiosis Global Market Report 2025
»óǰÄÚµå : 1760694
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,272,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,065,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,859,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÁøÆóÁõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 8.0%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü·Î 76¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀÇ ¿øµ¿·ÂÀº »ê¾÷ º¸°Ç ±âÁØ¿¡ ´ëÇÑ °ü½É Áõ°¡, ¸ÕÁö ±ÔÁ¦ °­È­, ±Ù·ÎÀÚ ¾ÈÀü Á¶Ä¡¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÁøÆóÁõ À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¶±â Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó µîÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Æó ¿µ»ó ±â¼úÀÇ ¹ßÀü, ÈÞ´ë¿ë È£Èí±â ÀåÄ¡ÀÇ Çõ½Å, AI¸¦ ÅëÇÑ Áúº´ °¨Áö °³¹ß, ¸ÕÁö °ü·Ã °Ç°­ ¹®Á¦¿¡ ´ëÇÑ R&D ÀÚ±Ý Áõ°¡, ¿þ¾î·¯ºí °ø±âÁú ¸ð´ÏÅ͸µ ¼¾¼­ÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

Èí¿¬ÀÇ È®»êÀº Æó¾Ï ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Èí¿¬Àº ´ã¹è, ½Ã°¡, ÆÄÀÌÇÁ µî ´ã¹è Á¦Ç°À» ÅÂ¿î ¿¬±â¸¦ ÈíÀÔÇϰųª ³»»Õ´Â ÇàÀ§·Î, Æó, ½ÉÀå, °Ç°­ Àü¹Ý¿¡ ¾Ç¿µÇâÀ» ¹ÌÄ¡´Â À¯ÇØÇÑ È­ÇÐÁ¦Ç°À» ¹æÃâÇÕ´Ï´Ù. Èí¿¬À²ÀÇ Áõ°¡´Â ´Ù¾çÇÑ ¿¬·ÉÃþ¿¡¼­ ´ÏÄÚÆ¾ Áßµ¶ÀÇ Áõ°¡¿Í ´ã¹è »ç¿ëÀÇ Áö¼ÓÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. Èí¿¬Àº Èí¿¬°ú °ü·ÃµÈ Æó ÁúȯÀÇ ¹ß»ý·üÀ» Áõ°¡½ÃÅ´À¸·Î½á ÁøÆóÁõÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 6¿ù °¡µð¾ðÁöÀÇ º¸µµ¿¡ µû¸£¸é 2023³â ÃÊ ¿µ±¹¿¡¼­ 14-17¼¼ û¼Ò³âÀÇ 14.5%°¡ ÀüÀÚ´ã¹è Á¦Ç°À» »ç¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â 2022³â 11.8%¿¡¼­ Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Èí¿¬À²ÀÇ Áõ°¡´Â Æó·Å ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù.

ÇコÄɾî ÁöÃâÀÇ Áõ°¡´Â Æó·Å ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄɾî ÁöÃâÀº °³ÀÎ, Á¤ºÎ ¹× Á¶Á÷ÀÌ ÀÇ·á ¼­ºñ½º, Ä¡·á ¹× °Ç°­ °ü·Ã Á¦Ç°¿¡ ÁöÃâÇÏ´Â ÃÑ ºñ¿ëÀÔ´Ï´Ù. ÀÇ·áºñ ÁöÃâÀÇ Áõ°¡´Â ÁÖ·Î Áö¼ÓÀûÀÎ Ä¡·á¿Í °ü¸®°¡ ÇÊ¿äÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁöÃâÀº Á¶±â Áø´Ü, Áö¼ÓÀûÀÎ ÀÇ·á, È£Èí±â Ä¡·á, Àü¹® Ä¡·á ¹× ¾à¹°¿¡ ´ëÇÑ Á¢±Ù¿¡ ÀÚ±ÝÀ» Áö¿øÇÔÀ¸·Î½á Æó·Å Ä¡·á¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù ¿µ±¹ Åë°èûÀÌ ¹ßÇ¥ÇÑ ¹Ù¿¡ µû¸£¸é, ¿µ±¹ÀÇ ÀÇ·áºñ ÁöÃâÀº 2022-2023³â »çÀÌ¿¡ 5.6% Áõ°¡ÇÏ¿© 2022³âÀÇ 0.9% Áõ°¡¿¡ ºñÇØ Å©°Ô Áõ°¡ÇÏ¿´½À´Ï´Ù. µû¶ó¼­ ÀÇ·áºñ ÁöÃâÀÇ Áõ°¡´Â Æó·Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pneumoconiosis refers to a group of lung diseases resulting from the prolonged inhalation of certain types of dust, leading to inflammation and scarring in the lung tissue. This damage can hinder the lungs' ability to efficiently exchange oxygen, causing symptoms such as shortness of breath, persistent coughing, and reduced exercise tolerance.

The primary types of pneumoconiosis include asbestosis, berylliosis, byssinosis, coal workers' pneumoconiosis, silicosis, and others. Asbestosis is a chronic condition caused by the prolonged inhalation of asbestos fibers. Treatment options for pneumoconiosis include medications, oxygen therapy, pulmonary rehabilitation, and others. These treatments may be administered orally, through inhalation, or other methods, while diagnostic approaches involve chest X-rays, computed tomography (CT) scans, lung function tests, and bronchoscopy. Various healthcare providers, such as hospitals, specialty clinics, and diagnostic centers, serve as end users for these treatments and diagnostic procedures.

The pneumoconiosis market research report is one of a series of new reports from The Business Research Company that provides pneumoconiosis market statistics, including the pneumoconiosis industry global market size, regional shares, competitors with the pneumoconiosis market share, detailed pneumoconiosis market segments, market trends, and opportunities, and any further data you may need to thrive in the pneumoconiosis industry. This pneumoconiosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumoconiosis market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing occupational exposure to coal dust, rising mining activities in unregulated regions, increasing neglect of worker health policies, growing delays in disease diagnosis, and rising cases of untreated respiratory issues.

The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth projected for the forecast period is driven by an increased focus on occupational health standards, stricter enforcement of dust control regulations, more investments in worker safety initiatives, greater awareness of pneumoconiosis risks, and improved access to early diagnostic services. Key trends anticipated during the forecast period include advancements in lung imaging technologies, innovations in portable respiratory devices, developments in AI-driven disease detection, increased funding for research into dust-related health issues, and advancements in wearable air quality monitoring sensors.

The widespread prevalence of smoking is expected to drive the growth of the pneumoconiosis market. Smoking involves inhaling and exhaling the smoke from burning tobacco products such as cigarettes, cigars, or pipes, which releases harmful chemicals that negatively impact the lungs, heart, and overall health. The rising prevalence of smoking is linked to increasing nicotine dependence and continued tobacco use across various age groups. Smoking contributes to pneumoconiosis by raising the incidence of lung diseases related to smoking. For example, in June 2023, The Guardian reported that 14.5% of 14 to 17-year-olds in the UK had used vaping products in early 2023, an increase from 11.8% in 2022. This growing smoking rate is driving the pneumoconiosis market forward.

Increasing healthcare expenditures are expected to contribute to the growth of the pneumoconiosis market. Healthcare expenditures represent the total financial outlay on medical services, treatments, and health-related products by individuals, governments, and organizations. The rising healthcare spending is mainly due to the growing incidence of chronic diseases, which require ongoing treatment and management. These expenditures support pneumoconiosis care by financing early diagnoses, continuous medical care, respiratory therapy, and access to specialized treatments and medications. For example, the Office for National Statistics reported in May 2024 that healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will accelerate the pneumoconiosis market's growth.

Leading companies in the pneumoconiosis market are focusing on the development of targeted drugs, such as oral small molecule drugs, to offer innovative treatment options that improve disease management and enhance the quality of life for those affected by occupational lung diseases. Oral small molecule drugs are made from low molecular weight compounds that can be ingested, absorbed into the bloodstream, and designed to target specific biological processes or proteins to treat diseases. For instance, in March 2022, Sino Biopharmaceutical Limited launched TDI01 suspension, a novel oral small molecule drug targeting ROCK2 for pneumoconiosis treatment. This groundbreaking drug, currently undergoing clinical trials, aims to offer a much-needed therapeutic option for the 900,000 people with pneumoconiosis in China, a condition that previously had no effective treatment.

Major players in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Gilead Sciences, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Veracyte Inc., Fidia Farmaceutici, PharmaMar, Verastem Inc., RS Oncology, Melinta Therapeutics LLC, Lupin

North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumoconiosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumoconiosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumoconiosis market consists of sales of protective equipment, diagnostic imaging systems, and therapeutic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumoconiosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumoconiosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pneumoconiosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumoconiosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pneumoconiosis Market Characteristics

3. Pneumoconiosis Market Trends And Strategies

4. Pneumoconiosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pneumoconiosis Growth Analysis And Strategic Analysis Framework

6. Pneumoconiosis Market Segmentation

7. Pneumoconiosis Market Regional And Country Analysis

8. Asia-Pacific Pneumoconiosis Market

9. China Pneumoconiosis Market

10. India Pneumoconiosis Market

11. Japan Pneumoconiosis Market

12. Australia Pneumoconiosis Market

13. Indonesia Pneumoconiosis Market

14. South Korea Pneumoconiosis Market

15. Western Europe Pneumoconiosis Market

16. UK Pneumoconiosis Market

17. Germany Pneumoconiosis Market

18. France Pneumoconiosis Market

19. Italy Pneumoconiosis Market

20. Spain Pneumoconiosis Market

21. Eastern Europe Pneumoconiosis Market

22. Russia Pneumoconiosis Market

23. North America Pneumoconiosis Market

24. USA Pneumoconiosis Market

25. Canada Pneumoconiosis Market

26. South America Pneumoconiosis Market

27. Brazil Pneumoconiosis Market

28. Middle East Pneumoconiosis Market

29. Africa Pneumoconiosis Market

30. Pneumoconiosis Market Competitive Landscape And Company Profiles

31. Pneumoconiosis Market Other Major And Innovative Companies

32. Global Pneumoconiosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumoconiosis Market

34. Recent Developments In The Pneumoconiosis Market

35. Pneumoconiosis Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â